Neuromuscular Deconditioning and Reconditioning in Colon Cancer Patients: an APA Muscle Rendorcement Program

NCT ID: NCT05099211

Last Updated: 2022-06-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-07-31

Study Completion Date

2025-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Colon cancer is a real public health problem with more than 46,000 new cases diagnosed per year in France and about 650 cases in Burgundy. Muscle deconditioning (MD), which is characterized by a loss of muscle mass and function, is a frequent consequence in cancer patients and conditions the prognosis. Therefore, it is essential to understand its complex etiology in oncology in order to address the real need for therapeutic countermeasures in clinical practice. DM is a multifactorial process that is exacerbated by therapies. It induces neurogenic and muscular alterations that can profoundly affect patients' quality of life.

Currently, analyses of this phenomenon in oncology have been limited essentially to a global evaluation of physical performance, neglecting the muscular and nervous nature of the adaptations responsible for it.

Most studies analyzing the therapeutic effects of physical activity (PA) have shown numerous physiological and psychological benefits of aerobic exercise. However, this form of PA is still not very effective in preserving muscle mass.

Only muscle strengthening can have an anabolic effect by accelerating the rate of protein synthesis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colon Cancer Muscle Strengthening

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients muscle strengthening

Group Type EXPERIMENTAL

Evaluation 2 post-surgery

Intervention Type OTHER

1. st visit:

* Body composition
* Nutritional assessment
* Psychometric tests of quality of life
2. nd visit:

* neuromuscular tests
* Functional tests
* Familiarization with training equipment if patient participates in re-training

Intermediate Evaluation 3

Intervention Type OTHER

performed 9 weeks after the beginning of training Identical tests to evaluation 1 + TM6

Final post-training evaluation 4

Intervention Type OTHER

Tests identical to evaluation 1 + TM6

Muscle biopsies

Intervention Type PROCEDURE

Optional

In pre-training:

Biopsy performed during the digestive surgery procedure

Final evaluation (minimum 1 day and maximum 7 days after the last training session): biopsy performed in the digestive surgery department.

Muscle Strengthening

Intervention Type OTHER

3 sessions per week for 18 weeks. Duration: 1 hour Training on different strength training machines for the main muscle groups of the lower and upper limbs. The training load will be gradually increased over the sessions.

Blood and urine samples

Intervention Type BIOLOGICAL

fasting blood sample taken at assessments 1, 2, 3 and 4 for patients and assessment 1 for controls

Evaluation 1 pre-surgery

Intervention Type OTHER

Carried out at least 15 days before surgery

1. st visit:

* Nutritional assessment
* Body composition
* Psychometric tests of quality of life + IPAQ Test
* VO2pic
2. nd visit:

* Neuromuscular tests
* Functional tests

Aerobic Training Patients

Group Type EXPERIMENTAL

Evaluation 2 post-surgery

Intervention Type OTHER

1. st visit:

* Body composition
* Nutritional assessment
* Psychometric tests of quality of life
2. nd visit:

* neuromuscular tests
* Functional tests
* Familiarization with training equipment if patient participates in re-training

Intermediate Evaluation 3

Intervention Type OTHER

performed 9 weeks after the beginning of training Identical tests to evaluation 1 + TM6

Final post-training evaluation 4

Intervention Type OTHER

Tests identical to evaluation 1 + TM6

Muscle biopsies

Intervention Type PROCEDURE

Optional

In pre-training:

Biopsy performed during the digestive surgery procedure

Final evaluation (minimum 1 day and maximum 7 days after the last training session): biopsy performed in the digestive surgery department.

Blood and urine samples

Intervention Type BIOLOGICAL

fasting blood sample taken at assessments 1, 2, 3 and 4 for patients and assessment 1 for controls

Aerobic Training

Intervention Type OTHER

3 sessions per week for 18 weeks. Duration: 1 hour Training on a "classic" pedal bicycle (called an ergocycle). The intensity and duration of the training will be gradually increased over the sessions and according to the patient's abilities.

Evaluation 1 pre-surgery

Intervention Type OTHER

Carried out at least 15 days before surgery

1. st visit:

* Nutritional assessment
* Body composition
* Psychometric tests of quality of life + IPAQ Test
* VO2pic
2. nd visit:

* Neuromuscular tests
* Functional tests

Healthy patients

Group Type ACTIVE_COMPARATOR

Blood and urine samples

Intervention Type BIOLOGICAL

fasting blood sample taken at assessments 1, 2, 3 and 4 for patients and assessment 1 for controls

Evaluation 1 pre-surgery

Intervention Type OTHER

Carried out at least 15 days before surgery

1. st visit:

* Nutritional assessment
* Body composition
* Psychometric tests of quality of life + IPAQ Test
* VO2pic
2. nd visit:

* Neuromuscular tests
* Functional tests

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Evaluation 2 post-surgery

1. st visit:

* Body composition
* Nutritional assessment
* Psychometric tests of quality of life
2. nd visit:

* neuromuscular tests
* Functional tests
* Familiarization with training equipment if patient participates in re-training

Intervention Type OTHER

Intermediate Evaluation 3

performed 9 weeks after the beginning of training Identical tests to evaluation 1 + TM6

Intervention Type OTHER

Final post-training evaluation 4

Tests identical to evaluation 1 + TM6

Intervention Type OTHER

Muscle biopsies

Optional

In pre-training:

Biopsy performed during the digestive surgery procedure

Final evaluation (minimum 1 day and maximum 7 days after the last training session): biopsy performed in the digestive surgery department.

Intervention Type PROCEDURE

Muscle Strengthening

3 sessions per week for 18 weeks. Duration: 1 hour Training on different strength training machines for the main muscle groups of the lower and upper limbs. The training load will be gradually increased over the sessions.

Intervention Type OTHER

Blood and urine samples

fasting blood sample taken at assessments 1, 2, 3 and 4 for patients and assessment 1 for controls

Intervention Type BIOLOGICAL

Aerobic Training

3 sessions per week for 18 weeks. Duration: 1 hour Training on a "classic" pedal bicycle (called an ergocycle). The intensity and duration of the training will be gradually increased over the sessions and according to the patient's abilities.

Intervention Type OTHER

Evaluation 1 pre-surgery

Carried out at least 15 days before surgery

1. st visit:

* Nutritional assessment
* Body composition
* Psychometric tests of quality of life + IPAQ Test
* VO2pic
2. nd visit:

* Neuromuscular tests
* Functional tests

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients who are \< 80 years old
* with a first diagnosis of colon cancer, regardless of TNM stage
* to undergo a scheduled excision surgery (laparoscopic colectomy or laparoscopy)
* with WHO stage \< 1 to the inclusion visit
* having given their written consent
* living close to the participating center (\<50 km)
* ability to understand instructions

Criteria for inclusion of healthy subjects :

* Adult who is \< 80 years old
* matched by gender, age and BMI to a patient
* with WHO stage \< 1 at visit V1
* no medical contraindications to the program
* having given written consent

Exclusion Criteria

* Criteria for exclusion of patients and healthy subjects :
* Protected Adult
* Person not affiliated to national health insurance
* Pregnant or breastfeeding woman
* uncontrolled hypertension
* Suffers from unstable diabetes of any type
* Suffers from heart disease. Pre-surgical VO2 test will confirm authorization.
* Affected by any condition likely to complicate the performance of physical activity (neurological, psychiatric, neuromuscular disorders, severe osteoporosis)
* Patient who received neo-adjuvant chemotherapy


\- Patient with rectal cancer or other evolving cancer


* Subject has had cancer in the last 5 years
* Subject with a high level of physical activity according to the IPAQ questionnaire

Criteria for exclusion of patients and healthy subjects for biopsy:

* Person with keloidosis
* Person with bleeding disorders, and/or on anticoagulant and antiaggregant medication
* hypersensitivity to lidocaine


* Patient with a WHO stage \> 1 at the V2 visit
* Presence of an ostomy (complicates PA practice)
* absence of post-operative chemotherapy treatment
* subject with a WHO stage \> 1 at the V2 visit
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre Hospitalier Universitaire Dijon

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Chu Dijon Bourgogne

Dijon, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Anaïs GOUTERON

Role: CONTACT

03 80 29 38 15

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Anaïs GOUTERON

Role: primary

03 80 29 38 15

Vanessa COTTET

Role: backup

03 80 39 34 87

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

COTTET CHU Dijon 2018

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Postoperative Electrical Muscle Stimulation Two
NCT06964438 NOT_YET_RECRUITING NA
Mechanistic Prehabilitation
NCT01919541 WITHDRAWN NA